Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 6/20 | 0.57 |
| ▸ | KCNA3 | P22001 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.39 |
| ▸ | HTR2A | P28223 | 2/20 | 0.39 |
| ▸ | HTR2C | P28335 | 2/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.39 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.39 |
| ▸ | GMNN | O75496 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL28025033 | 0.98 | KCNN4 (0.55) | KCNN4KCNA3TSHRLMNACYP19A1 | |
| SCHEMBL12555039 | 0.90 | KCNN4 (0.47) | KCNN4KCNA3TSHRLMNACYP19A1 | |
| SCHEMBL29262767 | 0.80 | KCNN4 (0.61) | KCNN4KCNA3TSHRLMNACYP19A1 | |
| SCHEMBL191706 | 0.80 | KCNN4 (0.52) | KCNN4KCNA3TSHRLMNACYP19A1 | |
| SCHEMBL12264150 | 0.78 | KCNN4 (0.50) | KCNN4KCNA3TSHRLMNACYP19A1 | |
| SCHEMBL3228004 | 0.78 | KCNN4 (0.55) | KCNN4TSHRLMNAMAPTTDP1 | |
| SCHEMBL2392958 | 0.77 | KCNN4 (0.49) | KCNN4KCNA3TSHRLMNACYP19A1 | |
| SCHEMBL12264151 | 0.76 | KCNN4 (0.47) | KCNN4KCNA3TSHRLMNACYP19A1 | |
| Hydrochloric Acid SCHEMBL2268778 | 0.75 | KCNN4 (0.52) | KCNN4TSHRLMNAMAPTTDP1 | |
| SCHEMBL27459558 | 0.74 | KCNN4 (0.72) | KCNN4KCNA3TSHRLMNACYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1600455-A1 | Preparation of solid phase bound peptides or PNAs | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2005-11-30 | — | — | EP | claimed |
| US-20050130228-A1 | Dosing form for a polymer support, use of said dosing form in organic chemical synthesis and method for production of said dosing form | H. LUNDBECK A/S (DK) | 2005-06-16 | — | — | US | claimed |
| US-20030138847-A1 | Dosing form for a polymer support, use of said dosing form in organic chemical synthesis and method for production of said dosing form | H. LUNDBECK A/S (DK) | 2003-07-24 | — | — | US | claimed |
| EP-1268050-A2 | DOSING FORM FOR A POLYMER SUPPORT, USE OF SAID DOSING FORM IN ORGANIC CHEMICAL SYNTHESIS AND METHOD FOR PRODUCTION OF SAID DOSING FORM | H. Lundbeck A/S (DK) | 2003-01-02 | — | — | EP | claimed |
| WO-2001068598-A2 | DOSING FORM FOR A POLYMER SUPPORT, USE OF SAID DOSING FORM IN ORGANIC CHEMICAL SYNTHESIS AND METHOD FOR PRODUCTION OF SAID DOSING FORM | H. LUNDBECK A/S (DK) | 2001-09-20 | — | — | WO | claimed |
| US-11014960-B2 | Amino acid and peptide conjugates and uses thereof | AUCKLAND UNISERVICES LIMITED (NZ) | 2021-05-25 | — | — | US | disclosed |
| US-20200392259-A1 | ORTHOMETALLATED CATALYST COMPONENTS FOR OLEFIN POLYMERIZATION AND COPOLYMERIZATION | ARZOUMANIDIS GREGORY G (US) | 2020-12-17 | — | — | US | disclosed |
| US-20200361864-A1 | Peptide Conjugates, Conjugation Process, and Uses Thereof | AUCKLAND UNISERVICES LTD (NZ) | 2020-11-19 | — | — | US | disclosed |
| US-20200353088-A1 | PEPTIDE CONJUGATE CGRP RECEPTOR ANTAGONISTS AND METHODS OF PREPARATION AND USES THEREOF | AUCKLAND UNISERVICES LIMITED (NZ) | 2020-11-12 | — | — | US | disclosed |
| US-20200306370-A1 | AMINO ACID AND PEPTIDE CONJUGATES AND CONJUGATION PROCESS | AUCKLAND UNISERVICES LTD (NZ) | 2020-10-01 | — | — | US | disclosed |
| EP-3215116-B1 | A HIGH MOLECULAR WEIGHT BIODEGRADABLE GELATIN-DOXORUBICIN CONJUGATE | UNIV OF THE SCIENCES IN PHILADELPHIA (US) | 2020-09-30 | — | — | EP | disclosed |
| EP-3707157-A1 | PEPTIDE CONJUGATE CGRP RECEPTOR ANTAGONISTS AND METHODS OF PREPARATION AND USES THEREOF | Auckland Uniservices Limited (NZ) | 2020-09-16 | — | — | EP | disclosed |
| EP-0983290-B1 | METHOD FOR PRODUCING POLYMERS HAVING NUCLEO-BASES AS SIDE-GROUPS | MORPHOCHEM AG (DE) | 2004-03-03 | — | — | EP | disclosed |
| US-20030138847-A1 | Dosing form for a polymer support, use of said dosing form in organic chemical synthesis and method for production of said dosing form | H. LUNDBECK A/S (DK) | 2003-07-24 | — | — | US | disclosed |
| EP-1268050-A2 | DOSING FORM FOR A POLYMER SUPPORT, USE OF SAID DOSING FORM IN ORGANIC CHEMICAL SYNTHESIS AND METHOD FOR PRODUCTION OF SAID DOSING FORM | H. Lundbeck A/S (DK) | 2003-01-02 | — | — | EP | disclosed |
| US-6355726-B1 | MULTICOMPONENT UGI REACTION; ANTISENSE AGENTS, ANTIGENS; DIAGNOSIS; CONTROLLING GENE EXPRESSION BY POLYMERIC PEPTIDE NUCLEIC ACIDS | MORPHOCHEM AG (DE) | 2002-03-12 | — | — | US | disclosed |
| WO-2001068598-A2 | DOSING FORM FOR A POLYMER SUPPORT, USE OF SAID DOSING FORM IN ORGANIC CHEMICAL SYNTHESIS AND METHOD FOR PRODUCTION OF SAID DOSING FORM | H. LUNDBECK A/S (DK) | 2001-09-20 | — | — | WO | disclosed |
| EP-0983290-A1 | METHOD FOR PRODUCING POLYMERS HAVING NUCLEO-BASES AS SIDE-GROUPS | Morphochem AG (DE) | 2000-03-08 | — | — | EP | disclosed |
| WO-1999004895-A1 | COMPOSITIONS FOR THE STORAGE AND DELIVERY OF SOLID PHASE REACTIVE PARTICLES AND METHODS OF USING THE SAME | ARGONAUT TECHNOLOGIES, INC. (US) | 1999-02-04 | — | — | WO | disclosed |
| WO-1998051697-A2 | METHOD FOR PRODUCING POLYMERS HAVING NUCLEO-BASES AS SIDE-GROUPS | MORPHOCHEM AG (DE) | 1998-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200353088-A1 | PEPTIDE CONJUGATE CGRP RECEPTOR ANTAGONISTS AND METHODS OF PREPARATION AND USES THEREOF | CALCRL, CALCR, GRPR | KCNN4 2869/4885KCNA3 1557/4885TSHR 282/4885 |
| US-20200306370-A1 | AMINO ACID AND PEPTIDE CONJUGATES AND CONJUGATION PROCESS | DNPEP, VIP, QPCT | KCNN4 4721/4885KCNA3 3720/4885TSHR 2067/4885 |
| US-20200361864-A1 | Peptide Conjugates, Conjugation Process, and Uses Thereof | VIP, NGLY1, PTMS | KCNN4 4823/4885KCNA3 4181/4885TSHR 2178/4885 |
| US-11014960-B2 | Amino acid and peptide conjugates and uses thereof | VIP, DNPEP, LNPEP | KCNN4 4717/4885KCNA3 3722/4885TSHR 1968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.